Royalty Report: Drugs, Cancer, Diagnostic – Collection: 233492

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Diagnostic
  • Disease
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233492

License Grant
For the Development License,  Licensor hereby grants to the Japanese Licensee, the co-exclusive, with Licensor, a license under the Licensed Technology, to conduct the Development Program, either in the Territory or outside of the Territory, as Licensee may determine is appropriate.

For the Commercialization License, Licensor grants an exclusive right and license throughout the Territory under the Licensed Technology, to develop, use, have used, make, have made, register, market, sell, have sold, export and import Products in the Field, and the right to make or have made the Compound used in the manufacture of the Products and/or the Products, either in the Territory or outside the Territory, for use for Products in the Territory and in the Field.

License Property
The patents relate to Methods of Detecting Lung Disease.

The licensed property is the Patents and Know-How relating to the Compound.

The Compound shall mean the chemical compound designated as INS316, whose chemical name is UTP (Uridine 5-Triphosphate).

INS316 Diagnostic is an inhaled diagnostic drug to aid in the detection of lung cancer and lung infection.

Method of Detecting Lung Disease
U.S. Patent No. 5,628,984

Method of Detecting Lung Disease
U.S. Patent No. 5,902,567

A Sterilized Isotonic and pH-Adjusted Pharmaceutical Formulation of Uridine Triphosphate
U.S. Patent No. 5,962,432

Novel Pharmaceutical Compositions of Uridine Triphosphate
U.S. Patent No. 5,968,913

Method of Detecting Lung Disease
U.S. National Phase Application of WO97/05195, U.S. Serial No. 08/776,772

Method of Detecting Lung Disease
U.S. Con. of #5 above; Filed 4 Nov 1999; Serial No. 09/433,757

Field of Use
INS316 Diagnostic to aid in the diagnosis of lung cancer and lung infection

The Field shall mean use as an acute use agent to facilitate production of a specimen for use in diagnosing, monitoring, staging or detecting diseases and/or infections. All therapeutic uses are expressly excluded from the Field.

IPSCIO Record ID: 291183

License Grant
University grants to Licensee to the extent of the Licensed Territory an exclusive license under the Patent rights and University Technology to make, have made, use and sell Licensed Products.
License Property
The patent is for Method of Treating Lung Disease with Uridine Triphosphates.

University owns and controls the inventions described in U.S. Patent No. 5,292,498 entitled 'Method of Treating Lung Disease with Uridine Triphosphates,' certain inventions relating to the therapeutic use of phenamil and benzamil for lung disease, and certain inventions relating to the diagnosis of AIDS-related Pneumocysitis carinii pneumonia ('PCP'), lung cancer, and tuberculosis (collectively, the 'Inventions').

Field of Use
The field is the therapeutic use of phenamil and benzamil for lung disease, and certain inventions relating to the diagnosis of AIDS-related Pneumoeysitis carinii pneumonia (PCP), lung cancer, and tuberculosis.

IPSCIO Record ID: 65273

License Grant
The Licensor grants grants the Licensee an exclusive, royalty-bearing, non-transferable , sublicensable license under the Licensed Patents and Technical Information,  relating to molecular diagnostics for lung cancer, solely to make, have made, use, sell, offer for sale, and import the Licensed Products in the Licensed Field in the Territory during the Term.
License Property
62/163,766 Methods and Compositions for Diagnosing or Detecting Lung Cancers – Patent rights and technical information and know-how relating to molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples.
Field of Use
This license pertains to the medical industry.  The Licensee  will obtain a license under such patent rights, technical information and know-how to develop and commercialize products for the non invasive cancer diagnostic testing including for lung cancer.

IPSCIO Record ID: 223142

License Grant
Licensor hereby grants to Licensee a royalty-bearing, exclusive right and license, with the right to sublicense as provided in this agreement, under the Licensed Patents and Know-How, to conduct research and to develop, make and have made, sell, offer to sell and have sold, import and have imported Licensed Products in the Field in the Territory; provided, however, that such license grant is subject to the restrictions set forth.
License Property
6,284,241 – Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
6,312,695 – Compounds and methods for therapy of lung cancer
6,660,838 – Compounds and methods for therapy and diagnosis of lung cancer

Licensed Patents shall mean the U.S. and foreign patents (including without limitation any reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions and additions of or to any of the foregoing) and patent applications (including without limitation any renewal, division, continuation, continued prosecution application or continuation-in-part of any of such applications) set forth.

Licensed Product shall mean any product in the Field that incorporates Know-How or at least one (1) Marker, the manufacture, use, sale, or import of which by Licensee or a Licensee sublicensee, would, but for the license granted herein, infringe one (1) or more of the Valid Claims of one (1) or more Licensed Patents or, in the case of Know-How, was utilized in the development, manufacturing, use or sale of a product.

Field of Use
Field shall mean the field of in vitro nucleic acid-based and antibody-based cancer diagnostics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.